Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Vita Therapeutics, a US-based startup developing cellular therapy treatments for muscular dystrophy, closed a $32m series A round on Wednesday led by its affiliate, biopharmaceutical company Cambrian Biopharma, and backed by Kiwoom Bio, SCM Life Sciences and Early Light Venture. Its technology is based on research by co-founders Douglas Falk (also its CEO) and Peter Andersen at Kennedy Krieger Institute, and Gabsang Lee and Kathryn Wagner at Johns Hopkins University.
Meetecho, an Italy-based developer of real-time web communication technology…
